Fasoracetam Cocrystal Forms for Higher Melting and Stable Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fasoracetam's low melting point poses challenges in manufacturing and storage, making it difficult to handle during tableting and packaging, and there is a need for solid forms with higher melting points to enhance processing convenience.
Innovation Solution
Development of crystalline compounds and cocrystals of fasoracetam with aromatic compounds and coformers such as urea, 4-aminobenzoic acid, trimesic acid, and others, which exhibit higher melting temperatures and improved physicochemical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If fasoracetam is used in its conventional monohydrate form, then it maintains its pharmacological activity, but it exhibits a low melting point (52-57°C) that causes processing difficulties during tableting and packaging
Solution Approach 1:
The patent applies cocrystal formation by combining fasoracetam with coformers (such as aromatic compounds, carboxylic acids, or amides) to create a composite crystalline material. This cocrystal structure fundamentally alters the thermal properties of fasoracetam, raising the melting point from 52-57°C to above 70°C, thereby resolving the processing difficulty while preserving pharmacological activity.
Solution Approach 2:
The patent changes the physical and chemical parameters of fasoracetam by forming cocrystals with different stoichiometric ratios and molecular arrangements. This parameter change transforms the melting point from a problematic low value (52-57°C) to a suitable high value (>70°C), enabling conventional manufacturing processes without requiring special temperature control.
2Ease of manufacture
If the melting point of fasoracetam is increased through cocrystal formation, then processing and storage become more convenient, but the crystal structure and potentially the bioavailability may be affected
Solution Approach 1:
The patent systematically evaluates multiple cocrystal forms with different coformers and stoichiometric ratios to identify formulations that simultaneously achieve high melting points (>70°C) and maintain adequate bioavailability. By adjusting parameters such as coformer type, molar ratio, and crystallization conditions, the patent optimizes both storage stability and pharmacological performance.
Solution Approach 2:
The cocrystal structure acts as an intermediary form that bridges the gap between the low-melting monohydrate and the desired high-melting stable form. The coformer molecules mediate the interaction, allowing fasoracetam to achieve improved thermal stability while the cocrystal lattice design ensures maintained solubility and bioavailability through appropriate molecular arrangement and hydrogen bonding patterns.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cocrystals provide enhanced melting points, stability, and bioavailability, addressing the handling issues of fasoracetam and facilitating more robust manufacturing and storage processes.
Implementation Method 1
cocrystals of fasoracetam and an organic coformer... The melting point of a cocrystal can be lower, higher or in between that of constituting components
Data Source
AI summary
The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.